KPTI - Karyopharm climbs over 25% most since early 2020 after strong revenue beat

Karyopharm Therapeutics (KPTI +26.8%) has added more than a quarter of value recording the biggest intraday gain since March 2020 after the company’s Q3 2021 revenue toped analyst estimates. Net product revenue for the quarter surged ~25% YoY to reach $26.7M as U.S. net product sales for cancer therapy XPOVIO reached $26.7M indicating ~32% growth from Q2 2021 and ~25% YoY rise. However, in H1 2021, XPOVIO net sales grew ~21% YoY reaching $41.9M. “XPOVIO continues to move earlier in the treatment paradigm following U.S. Food and Drug Administration (FDA) approval in the second-line plus treatment setting for multiple myeloma in December 2020,” CEO Richard Paulson, remarked. For the year, the company has kept the guidance for R&D expenses at $270M – $290M, excluding stock-based compensation expense. The cash runway is expected to be sufficient until mid-2023. The revenue beat comes at a time Karyopharm (NASDAQ:KPTI) has lost more than

For further details see:

Karyopharm climbs over 25% most since early 2020 after strong revenue beat